Overview

* NeoGenomics ( NEO ) Q3 revenue rises 12% to $188 mln, beating analyst expectations

* Net loss for Q3 increases 53% to $27 mln

* Adjusted EBITDA for Q3 declines 9% to $12 mln

Outlook

* NeoGenomics ( NEO ) reaffirms full-year 2025 guidance for revenue, net loss, and adjusted EBITDA

* Company expects clinical volume growth to drive Q4 performance and 2026 momentum

Result Drivers

* CLINICAL REVENUE GROWTH - Clinical revenue grew 18%, driven by increased test volumes and strategic reimbursement initiatives

* NGS REVENUE INCREASE - NGS revenue rose 24% YoY, now accounting for nearly one-third of clinical revenue

* OPERATING EXPENSES - Operating expenses rose 12% due to impairment charges and higher compensation costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $188 mln $183.76

Revenue mln (14

Analysts

)

Q3 $3.60

Adjusted mln

Net

Income

Q3 Net -$27 mln

Income

Q3 $12.20

Adjusted mln

EBITDA

Q3 Gross $80 mln

Profit

Q3 $107 mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy."

* Wall Street's median 12-month price target for Neogenomics Inc ( NEO ) is $11.00, about 7.6% above its October 27 closing price of $10.16

* The stock recently traded at 64 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)